- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 212 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 90 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 94 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen | |
| 24.10.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2025 | 173 | GlobeNewswire (Europe) | Back to organic growth Quarter July-September 2025Net sales amounted to SEK 127.2 million (130.4), corresponding to a decrease of 2.4 percent. Organic sales growth amounted to 1.7 percent, currency... ► Artikel lesen | |
| 13.10.25 | Boule Diagnostics AB: Boule Diagnostics Announces CFO Departure for New Opportunity | 112 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization.Torben Nielsen, CEO of Boule... ► Artikel lesen | |
| 18.07.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2025 | 387 | GlobeNewswire (Europe) | Strong instrument sales Quarter April-June 2025Net sales amounted to SEK 129.3 million (137.0), corresponding to a decrease of 5.6 percent. Organic sales growth amounted to -3.3 percent, currency effects... ► Artikel lesen | |
| 07.05.25 | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 7, 2025 in Boule Diagnostics | 361 | GlobeNewswire (Europe) | At the Annual General Meeting 2025 (the "AGM") it was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 28.04.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2025 | 344 | GlobeNewswire (Europe) | Transformative quarter
Quarter January-March 2025Net sales amounted to SEK 112.9 million (147.8), corresponding to a decrease of 23.6 percent. Organic sales growth amounted to -25.1 percent, currency... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 29,340 | -16,65 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Carl Zeiss Meditec vor Zahlen mit einem Kursziel von 50,55 Euro auf "Outperform" belassen. Das erste Quartal... ► Artikel lesen | |
| FRESENIUS | 48,470 | +1,74 % | Fresenius: Nach 5-Jahres-Hoch - Analysten weiter optimistisch | Der Trading-Tipp des Tages ist diesmal Fresenius. In diesem Jahr läuft es für die Aktie bisher sehr gut. Gestern erreichte das Papier sogar ein 5-Jahres-Hoch. Heute findet sich Fresenius zwar am DAX-Ende... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,110 | +1,10 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Siemens Healthineers mit einem Kursziel von 61,30 Euro auf "Overweight" belassen. Der Konzernchef sowie der Finanzvorstand hätten... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,490 | +2,35 % | Elmos, FMC, Gerresheimer, Hensoldt, Hypoport, Zalando: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| GERRESHEIMER | 27,300 | +9,20 % | Abend-Update: Insider sollen zugeschlagen haben: Gerresheimer plötzlich extrem gefragt - sofort prüfen! | ||
| BRIGHTSPRING HEALTH SERVICES | 39,590 | +0,97 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| GENEDX | 101,88 | +1,84 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 23,630 | +1,42 % | Alignment Healthcare stock price target raised to $28 by KeyBanc | ||
| PROGYNY | 24,990 | -1,81 % | Forecasting The Future: 6 Analyst Projections For Progyny | ||
| ANTERIS TECHNOLOGIES GLOBAL | 6,570 | +8,42 % | Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic | MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 30,770 | -0,55 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| ADAPTHEALTH | 10,500 | -0,28 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| RXSIGHT | 9,860 | -0,90 % | Expert Outlook: RxSight Through The Eyes Of 5 Analysts | ||
| HEARTFLOW | 33,470 | -0,24 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| BETA BIONICS | 16,505 | +0,27 % | Beta Bionics, Inc.: Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
BOULE DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,451 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOULE DIAGNOSTICS AB finden Sie auf Wallstreet Online.